Filtered By:
Drug: Diovan
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
In conclusion, this meta-analysis found no association between ARNI therapy and improved ASCVD events in patients with HF.PMID:37619492 | DOI:10.1016/j.amjcard.2023.07.154
Source: Atherosclerosis - August 24, 2023 Category: Cardiology Authors: Lis Victoria Ravani Douglas Mesadri Gewehr Pedro Calomeni Mateus de Miranda Gauza Jussara Pereira Rhanderson Cardoso Henrique Barbosa Ribeiro Edimar Bocchi Source Type: research

Angiotensin Receptor –Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
Sacubitril-valsartan is an angiotensin receptor –neprilysin inhibitor (ARNI) associated with a decreased risk of death and hospitalization for selected patients with heart failure (HF). However, its association with improved atherosclerotic cardiovascular disease (ASCVD) events remains unclear. We performed a meta-analysis to evaluate the assoc iation of ARNI with ASCVD events in patients with HF. We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarc...
Source: The American Journal of Cardiology - August 22, 2023 Category: Cardiology Authors: Lis Victoria Ravani, Douglas Mesadri Gewehr, Pedro Calomeni, Mateus de Miranda Gauza, Jussara Pereira, Rhanderson Cardoso, Henrique Barbosa Ribeiro, Edimar Bocchi Source Type: research

Comprehensive analysis of the diagnostic and therapeutic value of the hypoxia-related gene PLAUR in the progression of atherosclerosis
In this study, Plasminogen activator, urokinase receptor (PLAUR) was identified as an effective diagnostic marker for AS lesion progression by combining WGCNA and random forest algorithm. We validated the stability of the diagnostic value on multiple external datasets including humans and mice. We identified a significant correlation between PLAUR expression and lesion progression. We mined multiple single cell-RNA sequencing (sc-RNA seq) data to nominate macrophage as the key cell cluster for PLAUR mediated lesion progression. We combined cross-validation results from multiple databases to predict that HCG17-hsa-miR-424-5...
Source: Atherosclerosis - May 26, 2023 Category: Cardiology Authors: Chengyi Dai Yuhang Lin Source Type: research

The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
CONCLUSIONS: Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome. The low dose of sacubitril/valsartan is well tolerated and may be an acceptable alternative strategy.PMID:36990878 | DOI:10.1016/j.ejim.2023.03.019
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Jun Gu Yue Wang Chang-Qian Wang Jun-Feng Zhang Source Type: research

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
ConclusionThe vasodilative effects of S/V result in immediate reductions in SVRI, SBP, SV and CI. However, S/V induces reverse cardiac remodelling, which is apparent shortly after treatment initiation and leads to improvements of clinical, functional, echocardiographic, laboratory and haemodynamic variables.
Source: American Journal of Cardiovascular Drugs - September 22, 2022 Category: Cardiology Source Type: research

Cost Effectiveness of the First ‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
ConclusionsThis was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.
Source: PharmacoEconomics - September 8, 2022 Category: Health Management Source Type: research

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli Tags: Short Communication Source Type: research

IJERPH, Vol. 19, Pages 2089: ARNI in HFrEF & mdash;One-Centre Experience in the Era before the 2021 ESC HF Recommendations
Conclusions: Our current positive experience in ARNI therapy is limited to extremely severe patients with HFrEF. Regardless of the more advanced HF and HF comorbidities, the patients treated with ARNI presented similar mortality and rehospitalizations as the patients treated by standard therapy.
Source: International Journal of Environmental Research and Public Health - February 13, 2022 Category: Environmental Health Authors: Rafa ł Niemiec Irmina Morawska Maria Stec Wiktoria Kuczmik Andrzej S. Swinarew Arkadiusz Stanula Katarzyna Mizia-Stec Tags: Article Source Type: research

Subcutaneous implanted cardioverter ‐defibrillator in ventricular noncompaction, coronary artery disease and stroke
This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 13, 2021 Category: Cardiology Authors: Claudia St öllberger, Edmund Gatterer, Matthias Hasun, Zsuzsanna Arnold, Josef Finsterer Tags: CASE REPORT Source Type: research

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk.
CONCLUSION: In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population. PMID: 33403890 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research

A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy
AbstractPurpose of ReviewTo highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure.Recent FindingsLVH is a modifiable risk factor. Intensive BP lowering (systolic BP<  120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets. The optimal agents for inducing LVH regression include renin–angiotensinogen...
Source: Current Hypertension Reports - September 4, 2020 Category: Primary Care Source Type: research